Hashemian Mohammad Nasser, Mahrjerdi Hadi Z, Mazloumi Mehdi, Safizadeh Mona S, Shakiba Yadollah, Rahimi Firouzeh, Afarideh Mohsen, Zare Mohamad Ali, Tafti Mohammadreza Fallah, Sepidan Bahram Bohrani, Abtahi Mohammad Ali, Abtahi Seyed-Hossein
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Students Research Center, Tehran University of Medical Sciences, Tehran, Iran.
J Res Med Sci. 2017 Feb 16;22:16. doi: 10.4103/1735-1995.200266. eCollection 2017.
To compare the efficacy of subconjunctival administration of bevacizumab and different doses of sunitinib malate in reducing corneal neovascularization (CNV).
In this experimental study, central corneal cauterization was created in the right eye of fifty male Sprague-Dawley rats. On day 1 (1 week after cauterization), rats were randomly assigned into five treatment groups. Group control ( = 10) received subconjunctival injection of 0.02 ml of base saline solution. Group 1 ( = 10) received 0.02 ml of bevacizumab (25 mg/ml). Group 2, 3, and 4 ( = 10 for each group) were treated with 0.02 ml of sunitinib malate (10, 20, and 50 μg/ml, respectively). On days 1, 7, and 14, digital photographs of the cornea were taken, and the area of CNV was measured.
During the 2-week follow-up, CNV area in treatment groups was less than in control group ( < 0.05). On day 7, corneal avascular area was highest in Group 3 at 63%. On day 14, the area of CNV in Groups 2 and 3 was less than in Group 1 ( = 0.031 and 0.011, respectively), but the difference between Groups 2 and 3 was not statistically significant ( = 0.552). The decreased CNV area on day 14 in Group 4 was significant in comparison to bevacizumab, but it was not significant on day 7 ( = 0.25 on day 7 and 0.002 on day 14).
Subconjunctival sunitinib malate is more effective than bevacizumab in regressing CNV. This effect is more prominent on day 14.
比较结膜下注射贝伐单抗和不同剂量苹果酸舒尼替尼在减少角膜新生血管（CNV）方面的疗效。
在本实验研究中，对50只雄性Sprague-Dawley大鼠的右眼进行中央角膜烧灼。在第1天（烧灼后1周），将大鼠随机分为五个治疗组。对照组（n = 10）结膜下注射0.02 ml基础盐溶液。第1组（n = 10）注射0.02 ml贝伐单抗（25 mg/ml）。第2、3和4组（每组n = 10）分别用0.02 ml苹果酸舒尼替尼（分别为10、20和50 μg/ml）治疗。在第1、7和14天，拍摄角膜数码照片，并测量CNV面积。
在2周的随访期间，治疗组的CNV面积小于对照组（P < 0.05）。在第7天，第3组的角膜无血管面积最高，为63%。在第14天，第2组和第3组的CNV面积小于第1组（分别为P = 0.031和0.011），但第2组和第3组之间的差异无统计学意义（P = 0.552）。第4组在第14天CNV面积的减少与贝伐单抗相比有显著差异，但在第7天无显著差异（第7天P = 0.25，第14天P = 0.002）。
结膜下注射苹果酸舒尼替尼在消退CNV方面比贝伐单抗更有效。这种效果在第14天更为突出。
